Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome‐like Relapsed/Refractory acute lymphoblastic leukemia
- 16 April 2021
- journal article
- research article
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (4) , e14024
Abstract
Introduction: (Ph‐like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR‐ABL1 translocation.Case description: We reported an exceptional case of a child with relapsed Ph‐like ALL with IKZF1 gene deletion treated with high‐dose ruxolitinib as monotherapy, after multi‐agent chemotherapy. He remains in continued MRD‐negative leukemia remission with full donor chimerism at 12 months post‐HSCT.Discussion: The circumstance that makes our case featured is the usage of ruxolitinib as monotherapy. This report, we believe, is a pioneering report for a frequent disease with a high risk of failure for the outcome.Keywords
This publication has 19 references indexed in Scilit:
- Integration of ruxolitinib into dose‐intensified therapy targeted against a novel JAK2 F694L mutation in B‐precursor acute lymphoblastic leukemiaPediatric Blood & Cancer, 2016
- EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implicationsBlood, 2016
- Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2014
- Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusionHaematologica, 2013
- Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB–Positive Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2013
- Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET ProjectBlood, 2013
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic LeukemiaCancer Cell, 2012
- RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocationsInternational Journal of Hematology, 2011
- A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification studyThe Lancet Oncology, 2009
- Deletion ofIKZF1and Prognosis in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2009